Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced ...

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) ...

Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

-- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company ...

Artelo Biosciences, Inc. announced positive results from its first-in-human study of ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5) aimed at addressing unmet needs in pain ...

On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.

TIX100 is a small molecule that works by targeting thioredoxin-interacting protein (TXNIP), a detrimental protein that is elevated in people with diabetes and leads to beta cell death and pancreatic ...

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ...